Loss of Dnmt3a increases self-renewal and resistance to pegIFNα in JAK2-V617F-positive myeloproliferative neoplasms

被引:3
|
作者
Usart, Marc [1 ,2 ]
Stetka, Jan [1 ,2 ,3 ]
Paz, Damien Luque [4 ]
Hansen, Nils [1 ,2 ]
Kimmerlin, Quentin [1 ,2 ]
Fonseca, Tiago Almeida [1 ,2 ]
Lock, Melissa [1 ,2 ]
Kubovcakova, Lucia [1 ,2 ]
Karjalainen, Riikka [1 ,2 ]
Hao-Shen, Hui [1 ,2 ]
Boersch, Anastasiya [5 ,6 ,7 ]
El Taher, Athimed [5 ,6 ,7 ,8 ]
Schulz, Jessica [8 ]
Leroux, Jean-Christophe [8 ]
Dirnhofer, Stefan [9 ]
Skoda, Radek C. [1 ,2 ]
机构
[1] Univ Basel Hosp, Dept Biomed, Expt Hematol, Hebelstr 20, CH-4031 Basel, Switzerland
[2] Univ Basel, Hebelstr 20, CH-4031 Basel, Switzerland
[3] Palacky Univ, Fac Med & Dent, Dept Biol, Olomouc, Czech Republic
[4] Univ Angers, Nantes Univ, Ctr Hosp Univ Angers, Ctr Natl Rech Sci,Ctr Rech Cancerol & Immunol Inte, Angers, France
[5] Univ Basel, Dept Biomed, Bioinformat, Basel, Switzerland
[6] Univ Hosp Basel, Basel, Switzerland
[7] Swiss Inst Bioinformat, Basel, Switzerland
[8] ETH Honggerberg Zurich, Inst Pharmaceut Sci, Zurich, Switzerland
[9] Univ Hosp Basel, Inst Med Genet & Pathol, Basel, Switzerland
基金
瑞士国家科学基金会;
关键词
HEMATOPOIETIC STEM-CELLS; CLONAL HEMATOPOIESIS; POLYCYTHEMIA-VERA; INTERFERON-ALPHA; T-CELLS; MUTATIONS; JAK2-V617F; CLASSIFICATION; EXPRESSION; PROGNOSIS;
D O I
10.1182/blood.2023020270
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Pegylated interferon alfa (pegIFN- alpha ) can induce molecular remissions in patients with JAK2 -V617F-positive myeloproliferative neoplasms (MPNs) by targeting long-term hematopoietic stem cells (LT-HSCs). Additional somatic mutations in genes regulating LT-HSC self-renewal, such as DNMT3A , have been reported to have poorer responses to pegIFN alpha . We investigated whether DNMT3A loss leads to alterations in JAK2 -V617F LTHSC functions conferring resistance to pegIFN alpha treatment in a mouse model of MPN and in hematopoietic progenitors from patients with MPN. Long -term treatment with pegIFN alpha normalized blood parameters and reduced splenomegaly and JAK2 -V617F chimerism in single -mutant JAK2 -V617F ( VF ) mice. However, pegIFN alpha in VF ; Dnmt3a Delta / Delta ( VF;Dm Delta / Delta ) mice worsened splenomegaly and failed to reduce JAK2 -V617F chimerism. Furthermore, LT-HSCs from VF;Dm Delta / Delta mice compared with VF were less prone to accumulate DNA damage and exit dormancy upon pegIFN alpha treatment. RNA sequencing showed that IFN alpha induced stronger upregulation of in fl ammatory pathways in LT-HSCs from VF;Dm Delta / Delta than from VF mice, indicating that the resistance of VF;Dm Delta / Delta LT-HSC was not due tofailure in IFN alpha signaling. Transplantations of bone marrow from pegIFN alpha - treated VF;Dm Delta / Delta mice gave rise to more aggressive disease in secondary and tertiary recipients. Liquid cultures of hematopoietic progenitors from patients with MPN with JAK2 -V617F and DNMT3A mutation showed increased percentages of JAK2 -V617F-positive colonies upon IFN alpha exposure, whereas in patients with JAK2 -V617F alone, the percentages of JAK2 -V617F-positive colonies decreased or remained unchanged. PegIFN- alpha combined with 5-azacytidine only partially overcame resistance in VF;Dm Delta / Delta mice. However, this combination strongly decreased the JAK2 -mutant allele burden in mice carrying VF mutation only, showing potential to in fl ict substantial damage preferentially to the JAK2 -mutant clone.
引用
收藏
页码:2490 / 2503
页数:14
相关论文
共 50 条
  • [41] Cardiac hypertrophy associated with myeloproliferative neoplasms in JAK2V617F transgenic mice
    Shi, Kaiyao
    Zhao, Wanke
    Chen, Yun
    Ho, Wanting Tina
    Yang, Ping
    Zhao, Zhizhuang Joe
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2014, 7
  • [42] Hematopoietic fitness of JAK2V617F myeloproliferative neoplasms is linked to clinical outcome
    Abu-Zeinah, Ghaith
    Di Giandomenico, Silvana
    Choi, Daniel
    Cruz, Tatiana
    Erdos, Katie
    Taylor, Elwood, III
    Ritchie, Ellen K.
    Silver, Richard T.
    Scandura, Joseph M.
    BLOOD ADVANCES, 2022, 6 (18) : 5477 - 5481
  • [43] The impact of JAK2V617F mutation on Philadelphia-negative myeloproliferative neoplasms
    Sahin, Ezgi
    Yonal-Hindilerden, Ipek
    Hindilerden, Fehmi
    Aday, Aynur
    Nalcaci, Meliha
    TURKISH JOURNAL OF MEDICAL SCIENCES, 2022, 52 (01) : 150 - 165
  • [44] JAK2 V617F Mutation Prevalence in Myeloproliferative Neoplasms in Pernambuco, Brazil
    da Silva, Rafael Ramos
    Domingues Hatzlhofer, Betania Lucena
    de Faria Machado, Cintia Gonsalves
    de Melo Lima, Aleide Santos
    de Albuquerque, Dulcineia Martins
    Nunes dos Santos, Magnun Nueldo
    Fertrin, Kleber Yotsumoto
    Costa, Fernando Ferreira
    Araujo, Aderson da Silva
    Cavalcanti Bezerra, Marcos Andre
    GENETIC TESTING AND MOLECULAR BIOMARKERS, 2012, 16 (07) : 802 - 805
  • [45] New advances in the role of JAK2 V617F mutation in myeloproliferative neoplasms
    Zhang, Yongchao
    Zhao, Yue
    Liu, YuSi
    Zhang, Minyu
    Zhang, Jihong
    CANCER, 2024, 130 (24) : 4229 - 4240
  • [46] Endothelial Damage in JAK2V617F Myeloproliferative Neoplasms with Splanchnic Vein Thrombosis
    De Moner, Blanca
    Martinez-Sanchez, Julia
    Garrote, Marta
    Ramos, Alex
    Ventosa-Capell, Helena
    Moreno-Castano, Ana
    Nomdedeu, Meritxell
    Ojeda, Asuncion
    Escolar, Gines
    Garcia-Pagan, Joan Carles
    Arellano-Rodrigo, Eduardo
    Carreras, Enric
    Alvarez-Larran, Alberto
    Diaz-Ricart, Maribel
    THROMBOSIS AND HAEMOSTASIS, 2025,
  • [47] JAK2V617F mutation status and allele burden in classical Ph-negative myeloproliferative neoplasms in Japan
    Edahiro, Yoko
    Morishita, Soji
    Takahashi, Kochi
    Hironaka, Yumi
    Yahata, Yuriko
    Sunami, Yoshitaka
    Shirane, Shuichi
    Tsutsui, Miyuki
    Noguchi, Masaaki
    Koike, Michiaki
    Imai, Kiyotoshi
    Kirito, Keita
    Noda, Naohiro
    Sekiguchi, Yuji
    Tsuneda, Satoshi
    Ohsaka, Akimichi
    Araki, Marito
    Komatsu, Norio
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2014, 99 (05) : 625 - 634
  • [48] JAK2 V617F mutation in Iranian patients with myeloproliferative neoplasms: clinical and laboratory findings
    Poopak, Behzad
    Farshdousti Hagh, Majid
    Saki, Najmaldin
    Elahi, Fazel
    Rezvani, Hamid
    Khosravipour, Gelareh
    Jahangirpour, Mohammad Ali
    Bolouri, Shirin
    Golkar, Tolou
    Falah, Parviz
    TURKISH JOURNAL OF MEDICAL SCIENCES, 2013, 43 (03) : 347 - 353
  • [49] Calreticulin and JAK2V617F driver mutations induce distinct mitotic defects in myeloproliferative neoplasms
    Holl, Kristin
    Chatain, Nicolas
    Krapp, Susanne
    Baumeister, Julian
    Maie, Tiago
    Schmitz, Sarah
    Scheufen, Anja
    Brock, Nathalie
    Koschmieder, Steffen
    Moreno-Andres, Daniel
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [50] Loss of Ezh2 cooperates with Jak2V617F in the development of myelofibrosis in a mouse model of myeloproliferative neoplasm
    Yang, Yue
    Akada, Hajime
    Nath, Dipmoy
    Hutchison, Robert E.
    Mohi, Golam
    BLOOD, 2016, 127 (26) : 3410 - 3423